MPH Program student testing new treatment for Alzheimer’s
Researchers say a new drug, T-817, is on the horizon to slow the progression of Alzheimer's disease, and Vanderbilt is one of 50 clinical trial sites across the country testing the drug.
"It's basically a drug that is shown to have neuro-protective effects to prevent the early death of those brain cells that we're trying to protect in patients with Alzheimer's disease," said Vanderbilt researcher Dr. Leah Acosta.